MoonLake Immunotherapeutics
MLTX
MLTX
125 hedge funds and large institutions have $3.53B invested in MoonLake Immunotherapeutics in 2023 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 51 increasing their positions, 33 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
6.21% less ownership
Funds ownership: 105.3% → 99.09% (-6.2%)
16% less call options, than puts
Call options by funds: $39.7M | Put options by funds: $47.3M
40% less funds holding in top 10
Funds holding in top 10: 10 → 6 (-4)
Holders
125
Holding in Top 10
6
Calls
$39.7M
Puts
$47.3M
Top Buyers
| 1 | +$62.8M | |
| 2 | +$51.7M | |
| 3 | +$35M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.2M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$26.4M |
Top Sellers
| 1 | -$44.3M | |
| 2 | -$28.5M | |
| 3 | -$25.8M | |
| 4 |
BlackRock
New York
|
-$22.2M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$16.9M |